[1]
R. Scrivo, “Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome”, acmcr, vol. 6, no. 5, pp. 660–668, Oct. 2022.